Gustavo Viani: New Recommendations Advance Safer Lung Reirradiation
Gustavo Viani/sbradioterapia.com.br

Gustavo Viani: New Recommendations Advance Safer Lung Reirradiation

Gustavo Viani, Professor at Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn:

“Lung Reirradiation: From Clinical Feasibility to Safer, More Reproducible Practice

Reirradiation has become an increasingly important treatment option in thoracic oncology.

As survival improves, more patients develop locoregional recurrences or second primary lung cancers after previous radiotherapy. For selected patients, a second course of radiation may offer meaningful local control. However, the therapeutic window is often narrow.

In 2020, our group published a meta-analysis in the American Journal of Clinical Oncology, evaluating the effectiveness and safety of stereotactic ablative radiotherapy (SABR) for lung cancer after previous thoracic irradiation.

Across 20 studies involving 595 patients, we reported approximately 73% local control and 54% overall survival at two years.

These findings supported the clinical feasibility of reirradiation in selected patients, while highlighting the importance of treatment-related toxicity.

Six years later, the 2026 ESTRO–ReCOG consensus, published in Radiotherapy and Oncology, addresses another fundamental question:

How can we make lung reirradiation safer, more reproducible, and technically robust?

The recommendations emphasize:

  • Retrieval and evaluation of all previous radiotherapy courses.
  • Validated image registration and three-dimensional cumulative dose assessment.
    Biological dose conversion using EQD2/BED.
  • Individualized optimization based on cumulative organ-at-risk constraints.
  • Daily volumetric image guidance, prioritizing critical organ protection.
  • Adaptive replanning when anatomical changes compromise treatment safety.

One particularly important concept is that maximizing target coverage should not automatically take precedence over protecting previously irradiated critical structures.

Selective compromises in target coverage may be necessary when cumulative organ doses approach tolerance limits.

The field is evolving from demonstrating that reirradiation is possible toward understanding how to deliver it safely, consistently, and with better patient selection.

Nevertheless, important uncertainties remain, particularly regarding cumulative normal tissue tolerances, biological recovery, and the relationship between delivered dose and late toxicity.

Reirradiation is not simply a second radiation treatment. It is a new therapeutic decision constrained by the biological and dosimetric consequences of the first.”

Title: Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation

Authors: Gustavo Viani, Caio V. Arruda, Ligia I. De Fendi

Read the full article.

Title: How to plan and deliver lung cancer reirradiation: A consensus approach from the ESTRO reirradiation and lung focus groups and ReCOG

Authors: Lone Hoffmann, Charles K. Matrosic, Nicolaus Andratschke, Ane Appelt, Arnaud Beddok, Alanah Bergman, Aileen Duffton, Emma M. Dunne, Gregory N. Gan, Charles Mayo, Donna H. Murrell, Niall O’Dwyer, David Palma, Michael Velec, Jonas Willmann, Ellen Yorke, Marija Popovic, Charles B. Simone II

Read the full article.

You can also read:

Gustavo Viani: New Recommendations Advance Safer Lung Reirradiation